Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial

Table 2 Comparison of background demographics between the two groups, n (%)

	Double-stent group (n = 40)	Single-stent group (n = 38)	P value
Sex, male/female, n	20/20	16/22	0.4841
Age, mean ± SD, years	73 ± 11	71 ± 12	0.3332
Hypertension	12 (30.0)	17 (44.7)	0.1781
Diabetes	14 (35.0)	12 (31.6)	0.7491
Diagnostic method			0.0141
Biopsy	21 (52.5)	30 (78.9)	-
Imaging	19 (47.5)	8 (21.1)	-
Tumor location			0.3421
Head	37 (92.5)	35 (92.1)	-
Neck	1 (2.5)	2 (5.3)	-
Body	2 (5.0)	0 (0.0)	-
Tail	0 (0.0)	1 (2.6)	-
Tumor staging			0.6871
III stage	27 (67.5)	24 (63.2)	-
IV stage	13 (32.5)	14 (36.8)	-
Chemotherapy	16 (40.0)	11 (28.9)	0.3341
Analgesic			> 0.999
None	23 (57.5)	23 (60.5)	-
Nonopioid analgesic	16 (40.0)	15 (39.5)	-
Moderate opioid	1 (2.5)	0 (0.0)	-
Strong opioids	0 (0.0)	0 (0.0)	-

¹χ² test.

²Student’s t-test.

The double-stent group underwent endoscopic retrograde cholangiopancreatography with a fully-covered self-expandable metallic biliary stent and a pancreatic duct stent, while the single-stent group underwent a fully-covered self-expandable metallic biliary stent only.